Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Peggy A Thompson, Nathan P Young, Craig R Stumpf, Boreth Eam, Vikas K Goel, Joan Chen, Sarah Fish, Gregory S Parker, Adina Gerson-Gurwitz, Maria Barrera, Eric Sung, Jocelyn Staunton, Gary G Chiang, Christopher J Wegerski, Samuel Sperry, Kevin R Webster and Siegfried H Reich
Title eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers
URL https://mct.aacrjournals.org/content/18/12_Supplement/B133
Abstract Text Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Zotatifin Zotatifin 2 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
Zotatifin eFT226|eFT-226|eFT 226 Zotatifin (eFT226) is an eukaryotic initiation factor 4A1 (eIF4A1) inhibitor that promotes binding of eIF4A1 to the 5'-UTR in a sequence selective manner, which leads to repression of mRNA translation, including translation of the receptor tyrosine kinases FGFR1/2 and ERBB2 (HER2), and potentially results in induction of apoptosis and inhibition of tumor growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133, PMID: 32470302).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 amp colorectal cancer sensitive Zotatifin Preclinical - Cell line xenograft Actionable In a preclinical study, Zotatifin (eFT226) inhibited cell growth, and induced apoptosis in a FGFR2-amplified colorectal cancer cell line in culture, and inhibited tumor growth, and induced regression in a cell line xenograft model (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133). detail...
FGFR1 amp lung non-small cell carcinoma sensitive Zotatifin Preclinical - Cell line xenograft Actionable In a preclinical study, Zotatifin (eFT226) inhibited tumor growth in a cell line xenograft model of FGFR1-amplified non-small cell lung cancer (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133). detail...